SCHEMBL4747320

SCHEMBL4747320

CC(=O)c1ccc(OCc2ccccc2)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.59
MRGPRX4 Q96LA9 5/20 0.56
BRD4 O60885 1/20 0.55
PTGER1 P34995 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
NPC1 O15118 1/20 0.52
HPGD P15428 1/20 0.52
RAB9A P51151 1/20 0.52
S1PR5 Q9H228 1/20 0.52
MAPT P10636 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
SMPD1 P17405 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20463320 0.88 MAOB (0.64) MAOBMRGPRX4MEN1KMT2A
SCHEMBL229472 0.88 MRGPRX4 (0.69) MRGPRX4PTGER1HPGDRAB9AS1PR5
SCHEMBL20463366 0.87 MAOB (0.69) MAOBMRGPRX4
SCHEMBL3123036 0.86 MAOB (0.64) MAOBMRGPRX4BRD4SMN1; SMN2NPC1
SCHEMBL3212402 0.85 BRD4 (0.48) MAOBMRGPRX4BRD4PTGER1SMN1; SMN2
SCHEMBL7711853 0.85 MRGPRX4 (0.50) MAOBMRGPRX4BRD4PTGER1SMN1; SMN2
SCHEMBL2744895 0.85 PARP10 (0.59) MAOBMRGPRX4PTGER1SMN1; SMN2NPC1
SCHEMBL31031135 0.85 MRGPRX4 (0.56) MRGPRX4BRD4PTGER1SMN1; SMN2NPC1
SCHEMBL8512056 0.85 BRD4 (0.64) MRGPRX4BRD4PTGER1SMN1; SMN2NPC1
SCHEMBL8512033 0.84 SLC6A2 (0.57) MRGPRX4PTGER1SMN1; SMN2NPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170080095-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2017-03-23 US disclosed
US-20170037401-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES APOSENSE LTD. (IL) 2017-02-09 US disclosed
US-8198305-B2 1-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxy-d3-phenyl)ethanone substituted with deuterium ions; antipsycholtic agent CONCERT PHARMACEUTICALS INC. (US) 2012-06-12 US disclosed
US-8198305-B2 1-(4-(3-(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)propoxy)-3-methoxy-d3-phenyl)ethanone substituted with deuterium ions; antipsycholtic agent CONCERT PHARMACEUTICALS INC. (US) 2012-06-12 US disclosed
WO-2008128166-A1 DEUTERATED DERIVATIVES OF 4-(6-FLUORO-1, 2-BENZISOXAZOL-3-YL) PIPERIDINE COMPOUNDS CONCERT PHARMACEUTICALS INC. (US) 2008-10-23 WO disclosed
US-20080255194-A1 1,2-Benzisoxazol-3-yl Compounds CONCERT PHARMACEUTICALS INC. (US) 2008-10-16 US disclosed
US-20080255194-A1 1,2-Benzisoxazol-3-yl Compounds CONCERT PHARMACEUTICALS INC. (US) 2008-10-16 US disclosed
CN-1159797-A Aryloxy and arylthiopropanolamine derivative suseful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof SMITHKLINE BEECHAM PLC (GB) 1997-09-17 CN disclosed
US-4649160-A HYPOTENSIVE, ANTIARRHYTHMIA, ADRENERGIC BLOCKING AGENTS HOFFMANN-LA ROCHE INC. (US) 1987-03-10 US disclosed
EP-0041233-B1 SUBSTITUTED PHENOXY-AMINOPROPANOL DERIVATIVES, INTERMEDIATES AND PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1984-02-15 EP disclosed
EP-0041233-A1 Substituted phenoxy-aminopropanol derivatives, intermediates and processes for their production, and pharmaceutical preparations containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1981-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170080095-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, MBOAT1 MAOB 3450/4885MRGPRX4 1223/4885BRD4 2982/4885
US-20080255194-A1 1,2-Benzisoxazol-3-yl Compounds HTR5A, HTR1A, HTR3A MAOB 105/4885MRGPRX4 233/4885BRD4 242/4885
US-20170037401-A1 COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES ABCB4, LNPK, MBOAT1 MAOB 3450/4885MRGPRX4 1223/4885BRD4 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.